China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 27, 2017 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Michael Byrnes, Chief Financial Officer, will be presenting at the upcoming 16th Annual Needham Healthcare Conference being held April 4-5, 2017 at The Westin Grand Central in New York, New York. Ocera’s presentation will take place on April 4, 2017 at 4:20 PM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109
